Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05446298 · ClinicalTrials.gov registry record · Phase 2

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

A Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by OncoC4.

Active
Registry status
Phase 2
Development phase
58
Enrollment target
20
Study locations

NCT05446298 is a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer that is active but no longer recruiting, run by OncoC4. The registered enrollment target is 58 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05446298, a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, is active but no longer recruiting, sponsored by OncoC4.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
58 participants
Enrollment target
20
Study locations

Study Summary

This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.

Conditions Studied

Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma High Grade Serous Adenocarcinoma of Ovary

Interventions

  • DRUG Pembrolizumab
  • DRUG ONC-392

Study Locations (20)

Texas

  • Texas Oncology, P. A. - Austin, USOR. 417 - Austin
  • Texas Oncology, P.A., Fort Worth - USOR. 420 - Fort Worth
  • Texas Oncology, P. A. Woodlands - USOR, 418 - The Woodlands
  • Texas Oncology - Northeast Texas - USOR, 423 - Tyler

Arizona

  • Cancer Treatment Centers of America, Phoenix. 403 - Goodyear
  • Honor Health, USOR, 406 - Phoenix

Illinois

  • Sudarshan Sharma, MD. LTD. 414 - Hinsdale
  • Cancer Treatment Centers of America, Chicago. 410 - Zion

Kentucky

  • Baptist Health Lexington, 407 - Lexington
  • Norton Cancer Institute - St. Matthews, 416 - Louisville

Connecticut

  • Nuvance Health System, 401 - Danbury

Florida

  • Baptist MD Anderson Cancer Center, 404 - Jacksonville

Indiana

  • Northwest Cancer Centers - Dyer, IN - USOR, 422 - Dyer

Louisiana

  • Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409 - Shreveport

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2022-12-22
Est. Completion 2026-06-30
Phase Phase 2

Sponsor

OncoC4

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05446298

The ClinicalTrials.gov registry entry for NCT05446298 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The listed sponsor is OncoC4, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05446298 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, Arizona, Illinois.

Frequently Asked Questions

What is clinical trial NCT05446298 about?

NCT05446298 is a clinical study titled "ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer". This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.

What is the current status of trial NCT05446298?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2022-12-22. Estimated completion is 2026-06-30.

What conditions does trial NCT05446298 study?

This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Adenocarcinoma of Ovary.

What interventions are being tested in trial NCT05446298?

The interventions under investigation include: Pembrolizumab (DRUG), ONC-392 (DRUG).

Who is sponsoring clinical trial NCT05446298?

This trial is sponsored by OncoC4, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05446298 being conducted?

This trial has 20 study locations across Arizona, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Fallopian Tube Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.